Search results (1331)
« Back to PublicationsThe Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Solé C. et al, (2019), Cancers (Basel), 11
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Plummer ER. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
McMullin MFF. et al, (2019), British journal of haematology, 184, 161 - 175
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA. et al, (2019), Cancer, 125, 99 - 108
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
Banerji U. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Gilmore E. et al, (2019), J Oncol, 2019
Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J. and Mead AJ., (2019), Adv Biol Regul, 71, 55 - 68
Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation
Blagden SP. et al, (2019), MOLECULAR CANCER THERAPEUTICS, 18
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
Evans TRJ. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
OVPSYCH2: A randomised study of psychological support following chemotherapy for ovarian cancer
Howells L. et al, (2019), PSYCHO-ONCOLOGY, 28, 6 - 6
First-in-human Phase 1 study of f the bromondomain and extra-terminal motif inhibitor BAY 1238097: Emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Postel-Vinay S. et al, (2018), European Journal of Cancer
Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
Blagden SP. et al, (2018), Clinical Cancer Research, clincanres.2277.2018 - clincanres.2277.2018
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14
Alpelisib (BYL719) Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type ER+ Advanced Breast Cancer
Juric D. et al, (2018), JAMA Oncology
From Pioneer to Repressor: Bimodal foxd3 Activity Dynamically Remodels Neural Crest Regulatory Landscape In Vivo.
Lukoseviciute M. et al, (2018), Dev Cell, 47, 608 - 628.e6
From pioneer to repressor: Bimodal foxd3 activity dynamically remodels neural crest regulatory landscape in vivo
Lukoseviciute M. et al, (2018), Developmental Cell
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer.
Lyon PC. et al, (2018), Radiol Case Rep, 13, 1259 - 1266